Perrigo announces a joint development agreement with Cobrek Pharmaceuticals, and will invest $12.5 million in the company.
Perrigo announces that 3Q earnings more than doubled and that sales increased 39% from a year ago, but investors' even higher expectations causes the stock to fall.